



September 2015

Insulin Glargine (Toujeo®) 300 units per ml for type 1 or type 2 diabetes mellitus.

The New Therapies Subgroup discussed the above at its meeting on 15th September 2015. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMMG considered the use of Insulin Glargine Insulin Glargine – Toujeo® (300 units/mL), for type 1 (T1DM) and type 2 diabetes mellitus (T2DM).

The group recommends the use of 300 units/ml insulin glargine – Toujeo® as an option in patients who experience painful injections with high volumes of 100 units/ml insulin and providing there are adequate measures in place for the safe prescribing of higher strength insulin across the health economy. e.g the use of an [insulin passport](#) and ensuring that all insulin glargine products are prescribed by brand name.

In clinical trials, Toujeo® was shown to be non-inferior to Lantus in reducing HBA1c in both T1DM and T2DM.

To note that switching from Lantus® to Toujeo® is not straightforward, as the drugs are not bioequivalent and are not directly interchangeable. Higher doses of Toujeo® (approximately 10-18%) may be required to achieve similar levels of glucose control. *Please note that the Toujeo® SoloStar pre-filled pen provides a dose of 1 to 80 units in one injection.*

According to set criteria insulin glargine Toujeo® was deemed to be a high priority for funding for the specific patient population defined above.

Review date: September 2017

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm their risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.

Commissioning implications for CCGs

NTS Recommendation

Diabetes is a very high cost area both nationally and in all GM CCGs

There is a significant difference in costs per patient between GMCCGs for this marker.

Future commissioning implications

There are not expected to be any significant future financial or commissioning implications.

Formulary and Interface considerations

Insulin glargine is first line in the Formulary with the Lantus brand named. Toujeo would not be placed into Formulary as our positioning means it would not hit the "80:20" rule.

Insulin does not have a RAG status and would be considered as "green" i.e. suitable for initiation and ongoing prescribing within primary care.

Summary of impact

Impact is expected to be minimal.

Major area of risk / implications: primary care